Search

Supplemental material, sj-pdf-1-jop-10.1177_02698811211064720 for The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation by James J Rucker, Lindsey Marwood, Riikka-Liisa J Ajantaival, Catherine Bird, Hans Eriksson, John Harrison, Molly Lennard-Jones, Sunil Mistry, Francesco Saldarini, Susan Stansfield, Sara J Tai, Sam Williams, Neil Weston, Ekaterina Malievskaia and Allan H Young in Journal of Psychopharmacology

Denna mixed method studie undersöker tre församlingar som tidigare vuxit och i vilka man identifierat vissa kännetecken som antas bidra till just församlingstillväxt. Undersökningens kvantitativa del syftar till att undersöka om församlingarna har fortsatt växa. Den kvalitativa delen syftar till att undersöka om kännetecknen finns eller finns kvar i församlingarna. Empirin insamlas genom intervjuer med församlingsföreståndare/pastorer och enkätfrågor till desamma, samt insamling av medlemsstatistik för åren 2017–2021. Kodning och tematisering görs utifrån Klas Eriksson och Cahtrine Nygrens nio identifierade kännetecken hos växande församlingar och analyser sker med hjälp av Christian A. Schwarz teorier om 65-hypotesen och principmetoden. Resultatet visar att ingen av församlingarna längre kan betraktas som växande och att församlingarna i varierande grad kännetecknas av de nio kännetecken för växande församlingar som Eriksson och Nygren identifierat i sin forskning, och de kvalitativa särdrag hos växande församlingar som Schwarz och Schalk identifierat i sin forskning.

The primary purpose of this study was to investigate the attitudes towards English loanwords, "anglicisms", among Spanish-English bilinguals in the Metropolitan area of New York. According to the 2010 US Census, this area encompassed approximately 3.5 million people above the age of 5 speaking Spanish at home, excluding the quantity of people who have some knowledge of Spanish but who do not speak it at home. The method used was a direct one, whereby we sent out a questionnaire, inquiring about the acceptability of 6 anglicisms deemed "necessary" and 6 anglicisms deemed "superfluous" as well as inquiring about the informants’ attitudes towards not only the users of anglicisms but also towards the broader use in society. Given that our goal was to not only have an equal amount of women and men, but also to have 3 clearly defined age groups, for whom Spanish is the maternal language, our end result of 12 participants fitting that description was somewhat underwhelming which led to problems drawing relevant conclusions. Our main hypothesis was that we would find a higher generalized acceptance level towards anglicisms among our informants across all variables as compared to the wide disapproval found in the broader US bilingual population. In addition, we expected to see no major age-related differences in the attitudes and that men and women be equally accepting towards the necessary anglicisms but that women would show a lower level of approval towards the superfluous anglicisms. Our hypotheses were mostly borne out by our data other than for the one assuming no agerelated differences in attitudes towards our two categories of anglicisms. The results indicated a markedly lower acceptance level in the oldest age-group than in the 2 younger age-groups, but only for the superfluous kind, while the necessary anglicisms saw similar approval levels across all age-groups.

Neuroinflammation and microglial activation are significant processes in Alzheimer’s disease pathology. Recent genome-wide association studies have highlighted multiple immune-related genes in association with Alzheimer’s disease, and experimental data have demonstrated microglial proliferation as a significant component of the neuropathology. In this study, we tested the efficacy of the selective CSF1R inhibitor JNJ-40346527 (JNJ-527) in the P301S mouse tauopathy model. We first demonstrated the anti-proliferative effects of JNJ-527 on microglia in the ME7 prion model, and its impact on the inflammatory profile, and provided potential CNS biomarkers for clinical investigation with the compound, including pharmacokinetic/pharmacodynamics and efficacy assessment by TSPO autoradiography and CSF proteomics. Then, we showed for the first time that blockade of microglial proliferation and modification of microglial phenotype leads to an attenuation of tau-induced neurodegeneration and results in functional improvement in P301S mice. Overall, this work strongly supports the potential for inhibition of CSF1R as a target for the treatment of Alzheimer’s disease and other tau-mediated neurodegenerative diseases.

INTRODUCTION: Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a "Holy Grail" of AD research and intensively sought; however, there are no well-established plasma markers. METHODS: A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed. RESULTS: Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71). DISCUSSION: Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation. ispartof: ALZHEIMERS & DEMENTIA vol:15 issue:6 pages:776-787 ispartof: location:United States status: published

Introduction Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a “Holy Grail” of AD research and intensively sought; however, there are no well-established plasma markers. Methods A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed. Results Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71). Discussion Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.

Emmanuelle Weiller,1 Catherine Weiss,2 Christopher P Watling,3 Christopher Edge,3 Mary Hobart,2 Hans Eriksson,1 Maurizio Fava4–6 1H. Lundbeck A/S, Valby, Copenhagen, Denmark; 2Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA; 3Cambridge Medical Communication Ltd, Cambridge, UK; 4Division of Clinical Research of the MGH Research Institute, 5Department of Psychiatry, 6Clinical Trials Network & Institute (CTNI), Massachusetts General Hospital, Boston, MA, USA Objective: Patients with major depressive disorder (MDD) with inadequate response to antidepressant treatment (ADT) may suffer a prolonged loss of functioning. This review aimed to determine if self-rated functional measures are informative in randomized placebo-controlled studies of adjunctive therapy in patients with MDD and inadequate response to ADT. Methods: This was a systematic literature review of articles in any language from the MEDLINE database published between January 1990 and March 2017. Eligible studies met the following criteria: patients with MDD; inadequate response to at least one ADT; adjunctive therapy (pharmacological or otherwise) to ADT; placebo control group; randomized controlled trial or a post hoc analysis of a randomized controlled trial; reported a self-rated functioning scale. Study characteristics and functioning efficacy data were extracted. Results: A total of 2,090 discrete records were screened, 293 full-text articles were assessed for eligibility, and 26 studies were included. All studies were acute (6–12 weeks) except for one 52-week study. The only self-rated functioning scale used in the included studies was the Sheehan Disability Scale (SDS). Of the 13 adjunctive agents identified, aripiprazole, brexpiprazole, edivoxetine, and risperidone improved functioning versus placebo (p